一线选择性内放射治疗联合化疗对比单纯化疗治疗结直肠癌肝转移患者(FOXFIRE、SIRFLOX和FOXFIRE-Global):三项多中心、随机、3期试验的联合分析
该联合分析纳入FOXFIRE、SIRFLOX和FOXFIRE-Global三项随机3期试验,比较一线FOLFOX化疗联合钇-90树脂微球选择性内放射治疗(SIRT)与单纯FOLFOX化疗在结直肠癌肝转移患者中的疗效。共549例接受单纯FOLFOX、554例接受FOLFOX联合SIRT,中位随访43.3个月,两组总生存无差异(HR 1.04,95%CI 0.90-1.19;p=0.61),中位生存分别为22.6个月和23.3个月。作者认为在未选择患者中不推荐早期联合SIRT。
要点
- FOLFOX联合SIRT组与单纯FOLFOX组总生存无差异,HR 1.04(95%CI 0.90-1.19;p=0.61)。
- 中位生存FOLFOX联合SIRT组22.6个月(95%CI 21.0-24.5)对比单纯FOLFOX组23.3个月(95%CI 21.8-24.7)。
- 3-4级中性粒细胞减少FOLFOX联合SIRT组186/507(37%)对比单纯FOLFOX组137/571(24%)。
核心结论
- 在肝局限性和肝优势型结直肠癌肝转移患者中,一线FOLFOX化疗联合SIRT与单纯FOLFOX相比未改善总生存。
- 因此,在未选择的转移性结直肠癌患者中不推荐早期使用SIRT联合化疗。
- 为进一定明确SIRT在转移性结直肠癌中的作用,需要仔细选择患者并研究SIRT作为化疗后巩固治疗的作用。
研究设计与样本
- FOXFIRE、SIRFLOX和FOXFIRE-Global为在14个国家(澳大利亚、比利时、法国、德国、以色列、意大利、新西兰、葡萄牙、韩国、新加坡、西班牙、中国台湾、英国和美国)的医院和专科肝脏中心进行的随机3期试验。
- 纳入未经化疗的转移性结直肠癌患者(WHO体能状态0或1),肝转移不适合治愈性切除或消融,按1:1随机分配至奥沙利铂为基础化疗(FOLFOX)或FOLFOX联合单次SIRT(与化疗第1或2周期同步)。
- FOXFIRE中FOLFOX为OxMdG方案(奥沙利铂85 mg/m2静脉输注2小时,L-亚叶酸钙175 mg或D,L-亚叶酸钙350 mg静脉输注2小时,氟尿嘧啶400 mg/m2静脉推注后2400 mg/m2持续静脉输注46小时)。
- SIRFLOX和FOXFIRE-Global中FOLFOX为改良FOLFOX6方案(奥沙利铂85 mg/m2静脉输注2小时,亚叶酸钙200 mg,氟尿嘧啶400 mg/m2静脉推注后2400 mg/m2持续静脉输注46小时)。
- 随机化采用中央最小化法,分层因素为肝外转移、肝脏肿瘤累及程度、计划使用生物制剂和研究中心的。
主要发现
- 2006年10月11日至2014年12月23日期间,549例患者随机分配至单纯FOLFOX组,554例分配至FOLFOX联合SIRT组。
- 中位随访43.3个月(IQR 31.6-58.4)。
- 单纯FOLFOX组549例中411例(75%)死亡,FOLFOX联合SIRT组554例中433例(78%)死亡。
- 总生存无差异(HR 1.04,95%CI 0.90-1.19;p=0.61)。
- FOLFOX联合SIRT组中位生存22.6个月(95%CI 21.0-24.5),单纯FOLFOX组23.3个月(95%CI 21.8-24.7)。
临床怎么用
- 作者认为,在未选择的转移性结直肠癌患者中不推荐早期使用SIRT联合化疗。
- 作者提出需仔细选择患者并研究SIRT作为化疗后巩固治疗的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival. METHODS: FOXFIRE, SIRFLOX, and FOXFIRE-Global were randomised, phase 3 trials done in hospitals and specialist liver centres in 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, South Korea, Singapore, Spain, Taiwan, the UK, and the USA). Chemotherapy-naive patients with metastatic colorectal cancer (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or ablation were randomly assigned (1:1) to either oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plus single treatment SIRT concurrent with cycle 1 or 2 of chemotherapy. In FOXFIRE, FOLFOX chemotherapy was OxMdG (oxaliplatin modified de Gramont chemotherapy; 85 mg/m2 oxaliplatin infusion over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over 2 h, and 400 mg/m2 bolus fluorouracil followed by a 2400 mg/m2 continuous fluorouracil infusion over 46 h). In SIRFLOX and FOXFIRE-Global, FOLFOX chemotherapy was modified FOLFOX6 (85 mg/m2 oxaliplatin infusion over 2 h, 200 mg leucovorin, and 400 mg/m2 bolus fluorouracil followed by a 2400 mg/m2 continuous fluorouracil infusion over 46 h). Randomisation was done by central minimisation with four factors: presence of extrahepatic metastases, tumour involvement of the liver, planned use of a biological agent, and investigational centre. Participants and investigators were not masked to treatment. The primary endpoint was overall survival, analysed in the intention-to-treat population, using a two-stage meta-analysis of pooled individual patient data. All three trials have completed 2 years of follow-up. FOXFIRE is registered with the ISRCTN registry, number ISRCTN83867919. SIRFLOX and FOXFIRE-Global are registered with ClinicalTrials.gov, numbers NCT00724503 (SIRFLOX) and NCT01721954 (FOXFIRE-Global). FINDINGS: Between Oct 11, 2006, and Dec 23, 2014, 549 patients were randomly assigned to FOLFOX alone and 554 patients were assigned FOLFOX plus SIRT. Median follow-up was 43·3 months (IQR 31·6-58·4). There were 411 (75%) deaths in 549 patients in the FOLFOX alone group and 433 (78%) deaths in 554 patients in the FOLFOX plus SIRT group. There was no difference in overall survival (hazard ratio [HR] 1·04, 95% CI 0·90-1·19; p=0·61). The median survival time in the FOLFOX plus SIRT group was 22·6 months (95% CI 21·0-24·5) compared with 23·3 months (21·8-24·7) in the FOLFOX alone group. In the safety population containing patients who received at least one dose of study treatment, as treated, the most common grade 3-4 adverse event was neutropenia (137 [24%] of 571 patients receiving FOLFOX alone vs 186 (37%) of 507 patients receiving FOLFOX plus SIRT). Serious adverse events of any grade occurred in 244 (43%) of 571 patients receiving FOLFOX alone and 274 (54%) of 507 patients receiving FOLFOX plus SIRT. 10 patients in the FOLFOX plus SIRT group and 11 patients in the FOLFOX alone group died due to an adverse event; eight treatment-related deaths occurred in the FOLFOX plus SIRT group and three treatment-related deaths occurred in the FOLFOX alone group. INTERPRETATION: Addition of SIRT to first-line FOLFOX chemotherapy for patients with liver-only and liver-dominant metastatic colorectal cancer did not improve overall survival compared with that for FOLFOX alone. Therefore, early use of SIRT in combination with chemotherapy in unselected patients with metastatic colorectal cancer cannot be recommended. To further define the role of SIRT in metastatic colorectal cancer, careful patient selection and studies investigating the role of SIRT as consolidation therapy after chemotherapy are needed. FUNDING: Bobby Moore Fund of Cancer Research UK, Sirtex Medical.
引用
- Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017. PMID: 28781171. doi:10.1016/S1470-2045(17)30457-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。